key: cord-0826182-4jlnm8hf
authors: Banna, G. L.; Cantale, O.; Friedlaender, A.; Addeo, A.
title: Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy
date: 2020-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2020.08.1707
sha: 5ebc80c4426131fdcae3add5491a98ad50bd749b
doc_id: 826182
cord_uid: 4jlnm8hf

nan

Background: Brigatinib is a next-generation ALK inhibitor developed in ALK+ NSCLC initially pretreated with crizotinib and now in first line setting. The objective of this study was to assess efficacy and tolerance of brigatinib administrated in the French early access program (EAP).

Methods: This retrospective multicentric study included ALK+ advanced NSCLC patients pretreated with at least one anti-ALK tyrosine-kinase inhibitor (TKI), enrolled in the brigatinib French EAP. Primary endpoint was investigator-assessed progressionfree survival (PFS). The results cover the entire EAP period and are an update of the first data presented at ASCO 2019 (abstract #9045).

Results: 184 patients were included by 66 centers in France: median age: 60 AE12.7 years; never smokers: 78.3%; adenocarcinoma: 97.8%; median number of previous lines: 3AE1.3 and of ALK inhibitors : 2AE0.5 (crizotinib: 91.8%, ceritinib: 85.3%, alectinib: 9.2%). 50.0% of patients had performance status 0-1 and 67.6% more than 3 metastatic sites (brain metastases (BM): 71%, carcinomatous meningitis 7.1%). Overall response rate was 43.2%. With a median follow up of 27.5 months , median duration of brigatinib treatment was 4.9 months (95%CI 4.1-5.9) with 42.4% and 23.4% patients on treatment at 6 and 12 months. Median PFS was 4.8 months (95%CI: 3.8-5.6). OS from brigatinib initiation was 19.4 months (95%CI: 15.6-24.5) while 79.1% and 18.2% of patients received 1 and 2 post-brigatinib treatment, respectively. In patients with and without BM, OS was 21.8 (95%CI 15.6-35.4) and 18 (95%CI 12.4-24) months, respectively. For patients who received 1 (n¼23), 2 (n¼146) or 3 (n¼ 15) TKI before brigatinib start, OS from brigatinib initiation was 15.6 (95%CI 9.7-NR), 19.4 (95%CI 15.7-28.7) and 21.8 (3.3-39) months, respectively. 10.3% of patients had permanent treatment discontinuation due to treatment-related adverse events and 9.7% underwent dose adjustments without definitive interruption.

Conclusions: The analysis of the EAP confirms the efficacy of brigatinib in a cohort of heavily pretreated for ALK-positive advanced NSCLC patients.

Legal entity responsible for the study: Groupe Français de Pneumo-Cancérologie.

Disclosure: R. Descourt: Advisory/Consultancy, Travel/Accommodation/Expenses, symposium and lectures: Takeda; Advisory/Consultancy, Travel/Accommodation/Expenses, symposium and lectures: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses, symposium and lectures: Pfizer; Advisory/Consultancy, symposium and lectures: Boehringer Ingelheim; Advisory/Consultancy, Travel/ Accommodation/Expenses, symposium and lectures: MSD; Advisory/Consultancy, symposium and lectures: BMS; Advisory/Consultancy: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses, symposium and lectures: AstraZeneca. M. Pérol: Advisory/Consultancy, Research grant/ Funding (institution), symposium and lectures: Roche genentech , Pierre Fabre, AstraZeneca, Takeda; Advisory/Consultancy, symposium and lectures: Eli Lilly; Advisory/Consultancy, symposium and lectures: Pfizer; Advisory/Consultancy, Research grant/Funding (institution), symposium and lectures: Boehringer Ingelheim; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy, symposium and lectures: MSD; Advisory/Consultancy, symposium and lectures: BMS; Advisory/ Consultancy: Novartis; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy, Research grant/ Funding (institution), symposium and lectures: Takeda; Advisory/Consultancy, Research grant/ Funding (institution), symposium and lectures: AstraZeneca; Advisory/Consultancy, Research grant/ Funding (institution), symposium and lectures: Chugaï. D. Planchard: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses, clinical trial research: AstraZeneca; Honoraria (institution), Advisory/Consultancy, clinical trial research: BMS; Honoraria (institution), Advisory/ Consultancy, clinical trial research: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy: Celgene; Advisory/Consultancy, clinical trial research: Daïchi Sankyo; Honoraria (institution), Advisory/Consultancy, clinical trial research: Lilly; Honoraria (institution), Advisory/Consultancy, clinical trial research: Merck; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/ Expenses, clinical trial research: Novartis; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses, clinical trial research: Pfizer; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: prIME oncology; Honoraria (institution), Advisory/Consultancy: Peer CME; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses, clinical trial research: Roche; Advisory/Consultancy: Samsung. G. Rousseau-Bussac: Travel/Accommodation/ Expenses: Takeda; Travel/Accommodation/Expenses: Roche; Non-remunerated activity/ies: Astra-Zeneca; Non-remunerated activity/ies: Boehringer Ingelheim; Non-remunerated activity/ies: BMS; Non-remunerated activity/ies: Janssen Cilag; Non-remunerated activity/ies: Lilly; Non-remunerated activity/ies: Mundipharma; Non-remunerated activity/ies: MSD; Non-remunerated activity/ies: Novartis; Non-remunerated activity/ies: 

Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy

Conclusions: In our limited series, IO had a scarce impact on the risk of SARS-CoV-2related mortality, whilst CT, older age, PS 1 and a baseline pro-inflammatory systemic profile could be associated with a higher risk.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding. Background: Immune checkpoint inhibitors (ICI) represent a major change in nonsmall cell lung cancer (NSCLC) treatment, however robust biomarkers are needed. Emerging data suggest that features discovered by deep learning (DL) models from CT scan images using artificial intelligence (AI) algorithms can accurately predict outcomes. In this study, our objective was to explore the potential of AI-based DL radiomics models in patients with advanced NSCLC treated with ICI.

Methods: Pre-ICI CT scans were obtained from n¼141 patients with advanced NSCLC. Primary lung cancer lesions were annotated using Weasis medical viewer. PyRadiomics analyses were performed using published known open-source algorithms. In parallel, DeepRadiomics based on convolutional AI neural networks using the Imagia Evidens platform were used. Algorithms were designed by incorporating the baseline clinical characteristics and DL-features in multivariate models to predict overallresponse rate (ORR), progression-free survival (PFS) and overall survival (OS). Since long-term responders (LTR) with firstor second-generation EGFR TKIs are often noted in proportion of patients in real world, it would be valuable to determine patient characteristics associated with long-term responders considering sequential approach of EGFR TKI in the management of EGFR-mutant NSCLC.

Methods: We analyzed EGFR-mutant advanced NSCLC patients treated with first-line gefitinib, erlotinib or afatinib from Jan 2013 to Dec 2016. LTRs were defined as patients whose PFS is longer than 36 months. We compared patient characteristics and other clinical outcomes between LTR group and control group.

Results: Of the 931 patients treated with first-line EGFR-TKI other than osimertinib, 140 (15.0%) patients were LTRs; gefitinib (n¼85, 60.7%), erlotinib (n¼22, 15.7 %), and afatinib (n¼33, 23.6%), respectively. With median follow-up of 59.5 months, median PFS was 54.1 months and overall survival was not reached in the LTR group. Patients with recurrent disease (OR 0.40, p<0.001), Exon 19 deletion (OR 0.58, p¼0.007) and without wet pleura (OR 3.11, p<0.001), bone (OR 1.93, p¼0.003), CNS (OR 1.69, p¼0.018) or other extrathoracic organ (OR 7.09, p¼0.001) metastases were associated with LTRs.

Conclusions: In real world data, 15% of patients can achieve more than 3 years of treatment duration with firstor second-generation EGFR TKI alone. Given insufficient availability of osimertinib as first-line therapy in many countries and lack of established salvage therapy against osimertinib-resistant NSCLC, our results suggest that firstor second-generation EGFR TKIs can be considered for patients with recurrent disease, exon 19 deletion, and without wet pleura metastases as well as extrathoracic metastases.

The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest

1396P Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study

Immunotherapy with ICI is active in a minority of NSCLC patients. The identification of new biomarkers of efficacy is needed

Deaths, causes: PD Chest infection COVID-19 6 (75%)

No: Number; PD:Progressive Disease. a Not SARS-CoV-2-related. b SARS-CoV-2-related